Deals
Glaxo Said to Near Deal for Human Genome at $14 a Share
This article is for subscribers only.
GlaxoSmithKline Plc is nearing a deal to buy Human Genome Sciences Inc. at about $14 a share, a person with knowledge of the process said.
While the timing hasn’t been established, an announcement may come as soon as today, the person said. Glaxo’s earlier $13-a-share offer for Human Genome, which valued the Rockville, Maryland-based biotechnology company at $2.6 billion, is set to expire at 5 p.m. New York time July 20. The stock rose 3.1 percent to $14 in trading before the opening of U.S. markets.